PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Cabergoline - Parkinson's disease
PAD Profile : Cabergoline - Parkinson's disease Important
Keywords :
dopamine agonists, ergot-derived dopamine receptor agonists, Parkinsons disease, PD
Brand Names Include :
Cabaser, Dostinex
Important Information :
Not a 1st-line treatment option.
On-going toxicity monitoring required
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Ergot-derived Dopamine agonists (bromocriptine, pergolide, cabergoline) are NOT recommended as a first-line treatment option for Parkinson's disease and should be considered BLACK.
Ergot-derived Dopamine agonists (bromocriptine, pergolide, cabergoline) should only be considered as an adjunct to levodopa in Parkinson's disease patients:
- who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy AND
- whose symptoms are not adequately controlled with a non-ergot derived dopamine agonist (pramipexole, ropinirole).
NOT for primary care prescribing, although all RED drug prescribing should be recorded on the patient's practice records. On-going toxicity monitoring is required
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism